Company:  EXAGEN INC. (XGN)
Form Type:  DEF 14A
Filing Date:  4/29/2020 
CIK:  0001274737 
Address:  1261 LIBERTY WAY 
City, State, Zip:  VISTA, California 92081 
Telephone:  (760) 560-1501 
Fiscal Year:  12/31 
Last Trade
Last Trade: 
$12.75  
Change: 
0.04 (0.32%)  
Trade Time: 
Jul 02  
Market Cap: 
$161.16M
Trade XGN now with 

© 2020  
Description of Business
Exagen is dedicated to transforming the care continuum for patients suffering from debilitating and chronic autoimmune diseases by enabling timely differential diagnosis and optimizing therapeutic intervention. We have developed and are commercializing a portfolio of innovative testing products under our AVISE® brand, several of which are based on our proprietary Cell-Bound Complement Activation Products, or CB-CAPs, technology. CB-CAPs assess the activation of the complement system, a biological pathway that is widely implicated across many autoimmune and autoimmune-related diseases, including systemic lupus erythematosus, or SLE. Our goal is to enable rheumatologists to improve care for patients through the differential diagnosis, prognosis and monitoring of complex autoimmune and autoimmune-related diseases, including SLE and rheumatoid arthritis, or RA.
Register and access this filing in:     
  FORM DEF 14A
    Notice of Annual Meeting of Stockholders
    PROXY STATEMENT
    Proposal 1 - Election of Directors
    Proposal 2 - Ratification of Appointment of Independent ...
    Report of the Audit Committee of the Board
      NAME AND TITLE
    Executive and Director Compensation
      COMPENSATION TABLE
      OPTIONS
    Security Ownership of Certain Beneficial Owners and Management
      BENEFICIAL OWNERS
    Certain Relationships and Related Party Transactions
    2021 Stockholders' Proposals
    Other Matters
    Exagen's Annual Report on Form 10-K